Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced today that management is scheduled to participate in William Blair's 42nd Annual Growth Stock Conference, on June 9, 2022, at 11:20 a.m. CT.
Further details, a webcast link, and a replay of the presentation, if available, will be posted on the company's investor relations website at https://investors.ginkgobioworks.com/events.
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company's platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization, and therapeutics discovery. For more information, visit www.ginkgobioworks.com.
Ginkgo Bioworks Contacts:
INVESTOR CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.
MEDIA CONTACT:
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$11.20 |
| Daily Change: | -0.15 -1.32 |
| Daily Volume: | 1,029,857 |
| Market Cap: | US$518.780M |
April 22, 2025 April 10, 2025 February 21, 2025 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
